The report "Transplant Diagnostics Market by Technology (SSO-PCR, SSP-PCR, NGS, Sanger’s Sequencing), Products & Services (Instruments, Reagents, Software), Application (Diagnostics, Research), End User (Hospitals, Academia, Diagnostic Center) - Forecast to 2021", analyzes and studies the major market drivers, restraints, opportunities, and challenges in North America, Europe, Asia-Pacific, and the Rest of the World (RoW).

Browse 79 market data Tables and 60 Figures spread through 180 Pages and in-depth TOC on "Transplant Diagnostics Market

http://www.marketsandmarkets.com/Market-Reports/transplant-diagnostics-market-96374742.html
Early buyers will receive 10% customization on reports.

The Global Transplant Diagnostics Market Is Projected to reach USD 753.9 Million by 2021 From USD 535.0 Million in 2016, at a CAGR of 7.1%, during 2016 to 2021

Download PDF brochure@ http://www.marketsandmarkets.com/pdfdownload.asp?id=96374742

On basis of technology, the transplant diagnostics market is categorized into molecular assay technology [including PCR-based (Sequence-specific oligonucleotide and sequence-specific primer-PCR) and sequencing-based (next-generation sequencing and Sanger sequencing)] and non-molecular assay technology (includes serological and mixed lymphocyte culture assays). The molecular assay segment is expected to account for the larger share of the global transplant diagnostics market in 2016. The sequencing-based molecular assay segment is projected to grow faster than the PCR-based molecular assay segment, growing at a double-digit CAGR during 2016–2021.

Request sample of this report@ http://www.marketsandmarkets.com/requestsample.asp?id=96374742

Factors such as growing number of solid organ, soft tissue, and stem cell transplantations; technological advancements; and increased funding, research grants, and public-private investments are the key market drivers for the transplant diagnostics industry. However, high device costs associated with NGS and PCR-based devices and limited medical reimbursements for organ donation and transplantation procedure restrain the growth of the market to a certain extent. Furthermore, the technological shift from serological assays to gene-based HLA profiling and improving healthcare infrastructure across developing countries provide opportunities for players in the transplant diagnostics market. The significant gap between the number of organs donated and the number of organs required annually is a major challenge limiting the growth of the global transplant diagnostics market.

As of 2015, the key players in the transplant diagnostics market included Thermo Fischer Scientific, Inc. (U.S.), Immucor, Inc. (U.S), Olerup SSp AB (Sweden), QIAGEN, Inc. (Netherlands), Bio-Rad Laboratories, Inc. (U.S.), Affymetrix, Inc. (U.S.), Illumina Inc. (U.S.), Luminex Corporation, (U.S.), F. Hoffmann-La Roche Ltd. (Switzerland), and Abbott Laboratories, Inc. (U.S.), among others.